Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone

NCT05100862 2026-03-18

MAHOGANY

Phase 3 Recruiting

780 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06504940 2026-02-27

Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

Phase 2 Recruiting

69 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Phase 2 Recruiting

49 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07355699 2026-01-21

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Phase 4 Recruiting

88 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05326308 2025-09-23

ARIADNE

Recruiting

705 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05653271 2025-08-11

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Phase 1 Recruiting

42 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06566807 2024-08-22

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Phase 2 Recruiting

51 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06513234 2024-07-22

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06454968 2024-06-18

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05846750 2023-07-19

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Phase 2 Recruiting

59 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

Clinical Trials

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

MAHOGANY

Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

ARIADNE

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma